Victory Capital Management Inc. Purchases 150,363 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Victory Capital Management Inc. grew its holdings in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 36.5% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 562,269 shares of the company's stock after buying an additional 150,363 shares during the period. Victory Capital Management Inc. owned 0.45% of Apellis Pharmaceuticals worth $17,942,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of APLS. KBC Group NV lifted its position in Apellis Pharmaceuticals by 34.8% during the 3rd quarter. KBC Group NV now owns 2,632 shares of the company's stock valued at $76,000 after acquiring an additional 679 shares during the period. Wolverine Asset Management LLC bought a new position in shares of Apellis Pharmaceuticals during the third quarter valued at approximately $27,000. True Wealth Design LLC purchased a new position in shares of Apellis Pharmaceuticals during the third quarter valued at approximately $27,000. Toronto Dominion Bank boosted its position in shares of Apellis Pharmaceuticals by 4.2% in the 3rd quarter. Toronto Dominion Bank now owns 25,622 shares of the company's stock worth $739,000 after purchasing an additional 1,022 shares in the last quarter. Finally, US Bancorp DE grew its stake in shares of Apellis Pharmaceuticals by 70.0% in the 4th quarter. US Bancorp DE now owns 3,223 shares of the company's stock worth $103,000 after buying an additional 1,327 shares during the last quarter. Institutional investors own 96.29% of the company's stock.

Insider Transactions at Apellis Pharmaceuticals

In related news, insider Caroline Baumal sold 2,816 shares of the firm's stock in a transaction on Monday, January 6th. The stock was sold at an average price of $33.81, for a total value of $95,208.96. Following the transaction, the insider now directly owns 55,560 shares of the company's stock, valued at approximately $1,878,483.60. This trade represents a 4.82 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CAO James George Chopas sold 1,096 shares of the business's stock in a transaction dated Wednesday, January 22nd. The shares were sold at an average price of $30.43, for a total value of $33,351.28. Following the sale, the chief accounting officer now directly owns 48,138 shares of the company's stock, valued at $1,464,839.34. This represents a 2.23 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 65,934 shares of company stock worth $1,950,261 in the last 90 days. 6.80% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on APLS shares. Wedbush lowered their price objective on Apellis Pharmaceuticals from $30.00 to $29.00 and set a "neutral" rating for the company in a research note on Monday, March 3rd. JPMorgan Chase & Co. lifted their price target on Apellis Pharmaceuticals from $50.00 to $54.00 and gave the stock an "overweight" rating in a research report on Tuesday, March 4th. HC Wainwright reissued a "buy" rating and set a $57.00 price objective on shares of Apellis Pharmaceuticals in a research report on Monday, March 3rd. Royal Bank of Canada decreased their target price on shares of Apellis Pharmaceuticals from $26.00 to $25.00 and set a "sector perform" rating for the company in a report on Monday, March 3rd. Finally, The Goldman Sachs Group cut their price target on shares of Apellis Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating on the stock in a report on Monday, March 3rd. Eight research analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $45.53.

Remove Ads

Apellis Pharmaceuticals Stock Up 1.5 %

APLS stock opened at $25.52 on Wednesday. The company has a market cap of $3.20 billion, a price-to-earnings ratio of -12.57 and a beta of 0.92. The company has a debt-to-equity ratio of 1.91, a quick ratio of 3.73 and a current ratio of 4.36. The business's 50-day moving average is $28.82 and its two-hundred day moving average is $30.81. Apellis Pharmaceuticals, Inc. has a fifty-two week low of $23.77 and a fifty-two week high of $60.64.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last issued its quarterly earnings data on Friday, February 28th. The company reported ($0.29) earnings per share for the quarter, topping the consensus estimate of ($0.37) by $0.08. The firm had revenue of $212.50 million for the quarter, compared to analysts' expectations of $197.92 million. Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The business's quarterly revenue was up 45.2% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.73) EPS. As a group, analysts forecast that Apellis Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).

Want to see what other hedge funds are holding APLS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.